Series A
$11.2M
Open roles0
Total raised$11.2M
Team size1-10
Founded · Stage2014 · Series A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Pearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Why it matters
Signals from funding, traction, and product direction.
- Per the SEC Form D (filed 2026-04-02, first sale 2026-03-19), the offering totaled $11.15M across 21 investors under Rule 506(b); no lead investor or participating firms were disclosed publicly. CEO Eric Gornstein told Technical.ly the company has relied largely on grants and angel investors to reach this stage.
- Founded in 2014 as a Johns Hopkins spinout (originally MycoMed Technologies / MycoMedDx), the company raised ~$5M in prior non-dilutive funding from TEDCO, NSF, NIH and the Cystic Fibrosis Foundation, plus an oversubscribed $3.5M seed round in 2022.
- Pearl secured FDA 510(k) clearance for its MycoMEIA Aspergillus urine assay in August 2025 and holds CE approval for EU sales, making it rare for a Series A-stage biotech to have a commercial product — a fact CEO Gornstein highlighted in the raise.
- Pipeline products include a Pseudomonas detection assay for cystic fibrosis patients, backed by a strategic investment from the Cystic Fibrosis Foundation in June 2025 and a $1M CARB-X award in February 2025 for bacterial pneumonia detection.
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Focus areas
Series ABiotechnologyDiagnosticsHealthtech
No open roles on the board yet
We do not have indexed listings for Pearl Diagnostics right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts